Patiromer用于射血分数降低心力衰竭患者高钾血症管理:DIAMOND试验
DIAMOND试验在1195例射血分数降低心力衰竭(HFrEF)且当前或既往存在RAASi相关高钾血症的患者中,经patiromer导入期优化RAASi治疗使878例(84.6%)达到目标剂量后,将439例随机分配至patiromer组、439例至安慰剂组。结果显示patiromer组血清钾调整均值变化较安慰剂组低0.10 mmol/l,且高钾血症>5.5 mmol/l风险、MRA减量风险及高钾血症事件发生率均降低。
要点
- patiromer可降低HFrEF患者血清钾水平,调整均值变化差为-0.10 mmol/l。
- patiromer降低高钾血症>5.5 mmol/l风险(HR 0.63)及MRA减量风险(HR 0.62)。
- patiromer组与安慰剂组不良事件相似。
核心结论
- 在HFrEF患者中,patiromer与高剂量MRA联用可降低复发性高钾血症风险。
研究设计与样本
- 多中心随机双盲安慰剂对照试验,筛查1642例HFrEF伴当前或既往RAASi相关高钾血症患者,1195例进入patiromer导入期并优化RAASi治疗,878例(84.6%)达到目标剂量后随机分配439例至patiromer组、439例至安慰剂组。
主要发现
- 治疗结束时中位随访27周(IQR 13-43),patiromer组血清钾调整均值变化为+0.03 mmol/l,安慰剂组为+0.13 mmol/l,组间差为-0.10 mmol/l(95%CI -0.13, 0.07;P<0.001)。
- patiromer组高钾血症>5.5 mmol/l风险(HR 0.63;95%CI 0.45, 0.87;P=0.006)和MRA减量风险(HR 0.62;95%CI 0.45, 0.87;P=0.006)均低于安慰剂组。
- patiromer组总调整高钾血症事件/100人年低于安慰剂组(77.7 vs. 118.2;HR 0.66;95%CI 0.53, 0.81;P<0.001)。
- 高钾血症相关疾病调整事件(win ratio 1.53,P<0.001)和总RAASi使用评分(win ratio 1.25,P=0.048)均 favoring patiromer组。
- 两组不良事件相似。
关键数值与推荐
- 主要终点为血清钾调整均值变化的组间差异。
- 五个分层次要终点包括高钾血症>5.5 mmol/l风险、MRA减量风险、总调整高钾血症事件/100人年、高钾血症相关疾病调整事件及总RAASi使用评分。
临床怎么用
- 对于HFrEF伴RAASi相关高钾血症的患者,联用patiromer可能有助于维持RAASi目标剂量并降低高钾血症复发风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To investigate the impact of patiromer on the serum potassium level and its ability to enable specified target doses of renin-angiotensin-aldosterone system inhibitor (RAASi) use in patients with heart failure and reduced ejection fraction (HFrEF). METHODS AND RESULTS: A total of 1642 patients with HFrEF and current or a history of RAASi-related hyperkalemia were screened and 1195 were enrolled in the run-in phase with patiromer and optimization of the RAASi therapy [≥50% recommended dose of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor-neprilysin inhibitor, and 50 mg of mineralocorticoid receptor antagonist (MRA) spironolactone or eplerenone]. Specified target doses of the RAASi therapy were achieved in 878 (84.6%) patients; 439 were randomized to patiromer and 439 to placebo. All patients, physicians, and outcome assessors were blinded to treatment assignment. The primary endpoint was between-group difference in the adjusted mean change in serum potassium. Five hierarchical secondary endpoints were assessed. At the end of treatment, the median (interquartile range) duration of follow-up was 27 (13-43) weeks, the adjusted mean change in potassium was +0.03 mmol/l in the patiromer group and +0.13 mmol/l in the placebo group [difference in the adjusted mean change between patiromer and placebo: -0.10 mmol/l (95% confidence interval, CI -0.13, 0.07); P < 0.001]. Risk of hyperkalemia >5.5 mmol/l [hazard ratio (HR) 0.63; 95% CI 0.45, 0.87; P = 0.006), reduction of MRA dose (HR 0.62; 95% CI 0.45, 0.87; P = 0.006), and total adjusted hyperkalemia events/100 person-years (77.7 vs. 118.2; HR 0.66; 95% CI 0.53, 0.81; P < 0.001) were lower with patiromer. Hyperkalemia-related morbidity-adjusted events (win ratio 1.53, P < 0.001) and total RAASi use score (win ratio 1.25, P = 0.048) favored the patiromer arm. Adverse events were similar between groups. CONCLUSION: Concurrent use of patiromer and high-dose MRAs reduces the risk of recurrent hyperkalemia (ClinicalTrials.gov: NCT03888066).
引用
- Butler, Anker, Lund, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J. 2022. PMID: 35900838. doi:10.1093/eurheartj/ehac401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。